- Home
- ALGS vs MIRA Comparison
ALGS vs MIRA Comparison
Compare ALGS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | MIRA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 43.7M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ALGS | MIRA |
|---|---|---|
| Price | $4.90 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 121.7K | 118.9K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.01 | $0.90 |
| 52 Week High | $13.69 | $2.45 |
Technical Indicators
Market Signals| Indicator | ALGS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 47.12 |
| Support Level | N/A | $0.99 |
| Resistance Level | $6.82 | $1.22 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 7.63 | 25.90 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.